Literature DB >> 31144218

Psychopathological and psychiatric evaluation of patients affected by lipodystrophy.

Pasquale Fabio Calabrò1,2, Giovanni Ceccarini1, Alba Calderone1, Chita Lippi1, Paolo Piaggi3, Federica Ferrari1, Silvia Magno1, Roberto Pedrinelli2, Ferruccio Santini4.   

Abstract

PURPOSE: Lipodystrophy is a collection of rare disorders defined by complete or partial loss of adipose tissue, due to abnormal adipocyte production, function, or distribution; it shares the main metabolic complications with obesity. Aims of the present study were to investigate the psychopathological characteristics of non-HIV lipodystrophic patients in comparison with a group of obese patients, a group of patients affected by oncologic chronic illness, and a control group of healthy subjects.
METHODS: All participants were female: 16 non-HIV lipodystrophic women (mean age 42 ± 12 years), 20 women with breast cancer (adenocarcinoma with a positive sentinel lymph node in outpatients awaiting chemotherapy, mean age 44 ± 5 years), 20 obese women (mean age 40 ± 3 years), and 20 healthy women (mean age 40 ± 2 years). Each lipodystrophic patient received a psychiatric assessment, following the diagnostic criteria for DSM-5. Patients and controls received a battery of self-report instruments measuring general psychopathology, body image concerns, eating habits and food craving, and pain concerns. The following psychopathological rating scales were used: SCL-90-R (Symptom Check List) for general psychopathology, BUT (Body Uneasiness Test) for body image, FCQ-T (Food Cravings Questionnaire Trait) for food craving, and WHYMPI (West Haven Yale Multidimensional Pain Inventory) for multidimensional pain inventory.
RESULTS: The psychiatric assessment of the 16 lipodystrophic patients revealed: three lifetime mood disorder, six current mood disorder, six lifetime anxiety disorder, five current anxiety disorder, four current somatic symptom disorder with predominant pain, six current binge eating disorder, 11 eating disorder not otherwise specified, two borderline personality disorder, one obsessive-compulsive personality disorder, one avoidant personality disorder, and five personality disorder not otherwise specified. In SCL-90-R scale, the subscale sensitivity showed a significantly higher score in the lipodystrophic and oncologic groups compared to healthy subjects. The subscale paranoid ideation showed a significantly higher score in the lipodystrophic group vs all the other groups. The total score of BUT scale was significantly higher in the lipodystrophic compared to healthy subjects. In WHYMPI scale, the scores of pain interference and family support were significantly higher in the lipodystrophic group. The scores of negative responses were significantly higher in the lipodystrophic group vs healthy subjects. In FCQ-T scale, the score of Cues dimension in lipodystrophic patients was significantly lower as compared with all the other groups.
CONCLUSIONS: Our findings suggest that lipodystrophic patients have an increased prevalence of mood, anxiety, pain, and eating disorders. LEVEL OF EVIDENCE: Level III. Evidence obtained from case-control analytic study.

Entities:  

Keywords:  Body image; Chronic illness; Food craving; Lipodystrophy; Pain; Psychopathology

Mesh:

Year:  2019        PMID: 31144218     DOI: 10.1007/s40519-019-00716-6

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  3 in total

1.  Approach to the Patient With Lipodystrophy.

Authors:  Lindsay T Fourman; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 2.  Somatic symptom disorder: a scoping review on the empirical evidence of a new diagnosis.

Authors:  Bernd Löwe; James Levenson; Miriam Depping; Paul Hüsing; Sebastian Kohlmann; Marco Lehmann; Meike Shedden-Mora; Anne Toussaint; Natalie Uhlenbusch; Angelika Weigel
Journal:  Psychol Med       Date:  2021-11-15       Impact factor: 7.723

3.  Qualitative interviews in patients with lipodystrophy to assess the patient experience: evaluation of hunger and other symptoms.

Authors:  Susan A Martin; Robert J Sanchez; Oyebimpe Olayinka-Amao; Charles Harris; Sheri Fehnel
Journal:  J Patient Rep Outcomes       Date:  2022-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.